Carl L Gordon Buys $10M of BlossomHill Therapeutics Inc (BLSM) — SEC Form 4, Aug 12, 2026

Open-Market Net Purchase · SEC Form 4
+$10,000,000
Reporting Owner
Carl L Gordon
Director
TXN 2026-08-10 · FILED 2026-08-12
Equity Position 2.71M sh 0 → 2,714,279
Filing Lag 2 business days within 2-day SEC deadline
Form 4 · Statement of Changes in Beneficial Ownership

BlossomHill Therapeutics Inc

BLSM CIK 0001839970
All BlossomHill Therapeutics Inc insider activity
Filing Date
2026-08-12
Report Date
2026-08-12
Accession No.
0000947871-26-000785
Accepted At
2026-08-12 20:46 UTC
Reporting Owner
Name Relationship
Carl L Gordon CIK 0001282930
Director
Carl L Gordon at BlossomHill Therapeutics Inc Full insider history
Bought (12 mo) $10,000,000
Sold (12 mo) —
More from this insider at BlossomHill Therapeutics Inc
2026-08-10 Award — View
All filings by this insider at BlossomHill Therapeutics Inc
Non-Derivative Securities Transactions
Title Date Type Shares Price Net Total Post-Txn Ownership
Common StockF1F3F4 2026-08-10 C - Conversion 1,039,996 A — 1,039,996 Indirect See footnotes
Common StockF1F3F4 2026-08-10 C - Conversion 1,049,283 A — 2,089,279 Indirect See footnotes
Common StockF2F3F4 2026-08-10 P - Purchase 625,000 A $16.00 +$10,000,000 2,714,279 Indirect See footnotes
Derivative Securities Transactions
Title Strike Date Type Shares Price Expiration Underlying Ownership
Series A Preferred StockF1F1F1F3F4 2026-08-10 C - Conversion 1,039,996 D $0.00 1,039,996 Common Stock Indirect See footnotes
Series B Preferred StockF1F1F1F3F4 2026-08-10 C - Conversion 1,049,283 D $0.00 1,049,283 Common Stock Indirect See footnotes
Footnotes (4)
F1
Each share of Series A Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering on August 10, 2026 without payment of consideration. The Preferred Stock has no expiration date. Show more
F2
Reflects shares of the Issuer's Common Stock purchased in the Issuer's initial public offering. Show more
F3
These securities are held directly by OrbiMed Private Investments VIII, LP ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII. OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI VIII. Show more
F4
Each of the Reporting Person, OrbiMed Advisors, and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, or GP VIII is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. Show more

Related filings at BlossomHill Therapeutics Inc

5%+ Holders · 13D/G 4 filers

Latest Schedule 13D/G per filer; stakes the filer reported closed are left out.

Other insiders at BlossomHill Therapeutics Inc
All BlossomHill Therapeutics Inc insider activity
GET /v1/forms/4/0000947871-26-000785 API docs
View Original SEC Filing